Prevalence of extended spectrum &#946-lactamases (ESBLs) among clinical Enterobacteriaceae isolates obtained from private diagnostic laboratory in Kano - Nigeria

One hundred Gram negative bacterial isolates were collected from a private diagnostic center and identified by subjecting the isolates to biochemical tests using standard procedures. Confirmed Enterobacteriaceae isolates were further subjected to screening for extended spectrum â-lactamases (ESBLs) production using Clinical Laboratory Standards Institute (CLSI) breakpoint and Double Disc Synergy Test (DDST). Standard discs of Augmentin (AUG 30 ìg) {Optudisc} and Ceftriaxone (CXM 30 ìg) {Medireich} and Ceftazidime (CAZ 30 ìg) {Glaxo-Smithkline} were used in the screening. The results of CLSI breakpoint test showed that 87% were ESBLs producers viz: Citrobacter fruendii (3), Escherichia coli (46), Klebsiella pneumoniae (13), Morganella morganii (1), Proteus vulgaris (23) and Salmonella typhi (1) while that ofconfirmed ESBLs producers using DDST was 49%. These included Citrobacter fruendii (2), Escherichia coli (25), Klebsiella pneumoniae (7), Morganella morganii (1), Proteus vulgaris (13) and Salmonella typhi (1). The implication of the results is discussed